• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » LifeBond wins CE Mark, FDA fast track for LifeSeal surgical sealant

LifeBond wins CE Mark, FDA fast track for LifeSeal surgical sealant

April 18, 2016 By Brad Perriello

LifeBond closes $27m Series DLifeBond said today that it won CE Mark approval in the European Union for its LifeSeal surgical sealant for gastrointestinal resection procedures, and got on the fast track with the FDA for the surgical sealant.

LifeSeal is designed to minimize staple-line leakage during anastomosis or linear surgical repair of the GI tract, Caesarea, Israel-based LifeBond said.

The FDA’s expedited access pathway granted to LifeSeal is meant for medical devices with the potential to address unmet needs for life-threatening or irreversibly debilitating diseases. LifeBond said it’s in the final stages of preparing a new pivotal study for LifeSeal in the U.S. and Europe.

“Commercialization of a new product is a meaningful milestone. For 9 years, the LifeBond team has been pioneering new technology through thorough scientific investigations and successful clinical studies. At this juncture, it is especially important to remember our beginnings and acknowledge the co-founders of the company, entrepreneurs Orahn Preiss-Bloom and Ishay Attar,” CEO Gideon Sturlesi said in prepared remarks. “LifeSeal is a unique product that not only provides remedy to an unmet need and improves patient care, but also has the potential to benefit health economics by reducing the overall cost associated with post-surgical leakage management. In the next year we intend to introduce the product to select European markets and to continue the important work with the FDA to bring this very much needed product to the market in the U.S. as well.”

“LifeSeal offers surgical units and hospitals an innovative, high-quality surgical tool that both easily integrates into the surgical practice, and has been proven in clinical studies to make a major positive difference for patients. The CE Mark as well as the EAP designation are not simply formalities, but a confirmation of the significance of this product and the important benefits it can produce,” added chairman Ittai Harel, a managing general partner at Pitango Venture Capital.

Last August LifeBond closed a $27 million Series D equity round, with participation from Pitango, Adams Street Partners, Sino Biopharmaceutical and existing investors.

Filed Under: Food & Drug Administration (FDA), Regulatory/Compliance, Surgical Tagged With: CE Mark, LifeBond

More recent news

  • Accelus wins FDA clearance for MRI compatibility of FlareHawk spinal implants
  • Presidio wins FDA IDE for ultra-low frequency neuromod, hires new CFO
  • Epiminder study backs implantable EEG tech
  • Neurent Medical wins FDA nod for next-gen chronic rhinitis treatment
  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy